RxDoctor Payments DataLook up a doctor →

Larry Hollenbeck, MD

Neurology · North Kansas City, MONPI 1801857891

Payments from drug & device makers

$93,061in general payments, 2019–2025

Across 303 payments — averaging $307.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$87K
  • AbbVie$674
  • Novartis$573
  • Lilly USA, LLC$336
  • Supernus Pharmaceuticals, Inc.$288
  • AstraZeneca$269
  • plus $4K from 54 others
$3,737in research payments, 2019–2025

Across 3 payments — averaging $1245.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$4K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly5$87,374
AbbVie(2 entities)39$674
Novartis20$573
Lilly USA, LLC10$336
Supernus Pharmaceuticals, Inc.33$288
AstraZeneca8$269
UCB, Inc.13$259
Sanofi12$214
Vanda Pharmaceuticals Inc.4$185
Tersera Therapeutics LLC6$160
Argenx US, Inc.6$150
Eisai Inc.8$145
EMD Serono, Inc.9$137
Acadia Pharmaceuticals Inc9$135
Biogen10$135
Pfizer8$130
Amgen6$119
Lundbeck LLC6$114
Sunovion Pharmaceuticals Inc.5$100
Teva Pharmaceuticals USA, Inc.6$85
Kyowa Kirin, Inc.4$73
Amneal Pharmaceuticals LLC4$71
Genentech USA, Inc.3$63
CSL Behring2$59
Acorda Therapeutics, Inc3$56
Jazz Pharmaceuticals Inc.3$52
Ipsen Biopharmaceuticals, Inc2$50
Vertical Pharmaceuticals, LLC3$50
Abbott2$49
Catalyst Pharmaceuticals, Inc.2$48
Mallinckrodt Hospital Products Inc.3$48
Neurocrine Biosciences, Inc.3$48
Alnylam Pharmaceuticals Inc.3$48
Arbor Pharmaceuticals, Inc.3$47
Mallinckrodt Enterprises LLC2$43
Adamas Pharmaceuticals, Inc.3$42
Cycle Pharmaceuticals Inc2$42
Bristol Myers Squibb2$38
Promius Pharma LLC2$37
Saol Therapeutics Inc.2$34
Livanova USA, Inc.2$34
E.r. Squibb & Sons, L.L.C.2$30
Sumitomo Pharma America, Inc.2$29
Aprecia Pharmaceuticals, LLC2$29
ANI Pharmaceuticals, Inc.1$28
Microtransponder, Inc.1$28
Otsuka America Pharmaceutical, Inc.1$25
Neurelis, Inc.1$24
Tanabe Pharma America, Inc.1$23
GRT US Holding, Inc.1$23
Grifols USA, LLC1$21
Upsher-smith Laboratories LLC1$21
Ultragenyx Pharmaceutical Inc.1$19
Assertio Therapeutics, Inc.1$19
GE HealthCare1$18
Scilex Pharmaceuticals Inc.1$17
Banner Life Sciences, LLC1$16
Avanir Pharmaceuticals, Inc.1$15
Zyla Life Sciences, Inc.1$14
Aquestive Therapeutics, Inc.1$14

How this compares

$93,061 in reported general payments places this provider in the 85th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri →

Medicare billing

Part B allowed, 2024
$255,650
Medicare patients
637
Services billed
23,265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in North Kansas City

See the full list for Missouri →

Where these figures come from

Is this you, or does something look wrong? →